Becton Dickinson and Co
bd.comBecton Dickinson and Co (NYSE: BDX) is a medical technology company that develops, manufactures, and sells medical devices, diagnostic systems, and life science research tools. Revenue comes from transactional product sales across two reportable segments, BD Medical and BD Interventional, covering consumables, instruments, and single-use devices sold primarily to hospitals, clinical laboratories, ambulatory surgery centers, and research institutions. BD operates globally, with a substantial portion of revenue derived from international markets, exposing results to foreign currency fluctuations. The company spun off its Diabetes Care business as Embecta Corp. (NASDAQ: EMBC) on April 1, 2022. BD holds significant intellectual property across patents, trademarks, and trade secrets in the U.S. and internationally, with no single patent deemed material to the business as a whole, per the FY2025 10-K filed November 25, 2025. CEO Thomas E. Polen leads the company, and R&D activities are conducted across global centers in the United States, India, China, Singapore, and Ireland.
Products & Services
BD Medical: blood collection systems including safety-engineered wingsets, needles, and blood collection tubes; arterial blood gas devices; urine collection kits; automated blood culturing and tuberculosis culturing systems; microorganism identification and drug susceptibility systems; microbiology laboratory automation; molecular testing systems for infectious diseases and women's health; rapid diagnostic assays for respiratory infections; fluorescence-activated cell sorters and analyzers; antibodies, kits, and reagents for cell analysis and life science research; clinical oncology and immunological diagnostic reagents. BD Interventional: hernia and soft tissue repair products; biological and bioresorbable grafts; biosurgery products; BD Surgiphor Antimicrobial Irrigation System; BD ChloraPrep surgical infection prevention products; PTA balloon catheters; radio frequency ablation catheters; peripheral vascular stents; stent grafts; drug coated balloons; ports; biopsy products; endovascular fistula creation devices; atherectomy and thrombectomy systems; urine management and indwelling, intermittent, and external urine catheters; kidney stone management devices; targeted temperature management systems; fecal management devices.
Revenue Model
Transactional product sales of medical devices, diagnostic instruments, consumables, and single-use specialty products to hospitals, laboratories, ambulatory surgery centers, extended care facilities, and research customers. No subscription or recurring-fee model is disclosed in the filing excerpts.
Customers & Markets
Hospitals, ambulatory surgery centers, individual healthcare professionals, clinical laboratories, extended care and alternate site facilities, homecare patients, pharmaceutical and biotechnology companies, academic institutions, government laboratories, and private research foundations. End markets include clinical diagnostics, surgical specialties, vascular and urology intervention, oncology, life science research, and infectious disease testing.
Geographic Exposure
Global operations with a substantial portion of revenue from international markets outside the United States. Significant R&D presence in North America, Greater Asia, and Europe. International revenues subject to foreign currency exchange rate risk. Governments in China and other countries apply price controls, volume-based procurement programs, and competitive bidding mechanisms that affect revenue.
Financial Snapshot
Loading...
